

01/21/00

004499760-042400

01-24-00

Box 509

A

Please type a plus sign (+) inside this box → ☒ PTO/SB/05 (1/98)  
Approved for use through 09/30/2000. OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 4285US  
First Inventor or Application Identifier Elsa A.J.M. Goulmy et al  
Title THE HA-1 ANTIGEN  
Express Mail Label No. EL500245792US

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

- ☒ \* Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original, and a duplicate for fee processing)
- ☒ Specification [Total Pages 42]  
(preferred arrangement set forth below)
  - Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
- ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 12]
- Oath or Declaration [Total Pages]
  - ☐ Newly executed (original or copy)
  - ☐ Copy from a prior application (37 C.F.R. § 1.63(d))  
(for continuation/divisional with Box 17 completed)  
[Note Box 5 below]
    - ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).
- ☒ Incorporation By Reference (useable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

- ☐ Microfiche Computer Program (Appendix)
- Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - ☒ Computer Readable Copy
  - ☒ Paper Copy (identical to computer copy)
  - ☒ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

- ☐ Assignment Papers (cover sheet & document(s))
- ☐ 37 C.F.R. § 3.73(b) Statement ☐ Power of Attorney  
(when there is an assignee)
- ☐ English Translation Document (if applicable)
- ☒ Information Disclosure Statement (IDS)/PTO-1449 ☒ Copies of IDS Citations
- ☒ Preliminary Amendment
- ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
- \* Small Entity ☐ Statement filed in prior application, Status still proper and desired  
(PTO/SB/09-12)
- ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
- ☒ Other: Abstract.....

\* A new statement is required to be entitled to pay small entity fees, except where one has been filed in a prior application and is being relied upon.

## 17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment.

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: PCT/ML98/00424  
Prior application information: Examiner \_\_\_\_\_ Group / Art Unit: \_\_\_\_\_

## 18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label ☒ Correspondence address below  
(Insert Customer No. or Attach bar code label here)

Name	Allen C. Turner				
	Trask, Britt & Rossa				
Address	P.O. Box 2550				
City	Salt Lake City	State	Utah	Zip Code	84110
Country	U.S.A.	Telephone	(801) 532-1922	Fax	(801) 531-9168

Name (Print/Type)	Allen C. Turner	Registration No. (Attorney/Agent)	33,041
Signature		Date	01/21/00

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Application of:**

Goulmy et al.

**Serial No.:** To be assigned

**Filed:** 21 January 2000

**For:** THE HA-1 ANTIGEN

**Examiner:** To be assigned

**Group Art Unit:** To be assigned

**Attorney Docket No.:** 4285US

**NOTICE OF EXPRESS MAILING**

Express Mail Mailing  
Label Number: EL500245792US

Date of Deposit with USPS: January 21, 2000

Person making Deposit: Jared Turner

**Preliminary Amendment**

Box Patent Application  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Before calculation of the filing fee, please amend the referenced application as follows:

**IN THE SPECIFICATION:**

Page 2, line 2, after "Title: The HA-1 Antigen", please insert

–Cross-reference to related application: This application is a continuation of co-pending, co-

owned International Application No. PCT/NL98/00424, filed on 23 July 1998, designating the United States of America, which itself claims priority from EP 97202303.0 filed on 23 July 1997.--

Page 5, line 23, please change "ofmHag" to --of mHag--.

Page 5, line 36, after "VLXDDLLEA" please insert --(SEQ.I.D. NO. 1)--.

Page 7, line 5, after "VLHDDLLEA" please insert --(SEQ.I.D. NO. 2)--.

Page 14, line 13, after "YXTDRVMTV" please insert --(SEQ.I.D. NO. 3)--.

Page 14, line 27, after "VXHDDXXEA" please insert --(SEQ.I.D. NO. 4)--.

Page 14, line 30, after "VLHDDLLEA" please insert --(SEQ.I.D. NO. 2)--.

Page 14, line 31, after "VLHDDLLEA" please insert --(SEQ.I.D. NO. 2)--.

Page 15, line 2, after "VLHDDLLEA" please insert --(SEQ.I.D. NO. 2)--.

Page 15, line 4, after "VLHDDLLEA" please insert --(SEQ.I.D. NO. 2)--.

Page 15, line 5, after "VLRDDLLEA" please insert --(SEQ.I.D. NO. 5)--.

Page 15, line 18, after "VLHDDLLEA" please insert --(SEQ.I.D. NO. 2)--.

Page 16, line 26, after "VLRDDLLEA" please insert --(SEQ.I.D. NO. 5)--.

Page 16, line 33, after "VLRDDLLEA" please insert --(SEQ.I.D. NO. 5)--.

Page 17, line 7, after "VLRDDLLEA" please insert --(SEQ.I.D. NO. 5)--.

Page 17, line 10, after "VLRDDLLEA" please insert --(SEQ.I.D. NO. 5)--.

Page 17, line 13, after "VLRDDLLEA" please insert --(SEQ.I.D. NO. 5)--.

Page 17, line 17, after "VLRDDLLEA" please insert --(SEQ.I.D. NO. 5)--.

Page 25, line 23, after "A-3" please insert --(SEQ.I.D. NO. 6)--.

Page 25, line 25, after "T-3" please insert --(SEQ.I.D. NO. 7)--.

Page 25, line 26, after "G-3" please insert --(SEQ.I.D. NO. 8)--.

Page 26, line 3, after "A-3" please insert --(SEQ.I.D. NO. 9)--.

Page 26, line 4, after "G-3" please insert --(SEQ.I.D. NO. 10)--.

Page 26, line 11, after "C-3" please insert --(SEQ.I.D. NO. 11)--.

Page 26, line 13, after "A-3" please insert --(SEQ.I.D. NO. 12)--.

In table 1, page 38, line 4, after "CCG" please insert --(SEQ.I.D. NO. 13)--.

In table 1, page 38, line 5, after "R R" please insert --(SEQ.I.D. NO. 14)--.

In table 1, page 38, line 7, after "CCG" please insert --(SEQ.I.D. NO. 15)--.

In table 1, page 38, line 8, after "R R" please insert --(SEQ.I.D. NO. 16)--.

In table 1, page 38, line 11, after "CCG" please insert ~~-(SEQ.I.D. NO. 13)-~~.

In table 1, page 38, line 12, after "R R" please insert ~~-(SEQ.I.D. NO. 14)-~~.

In table 1, page 38, line 13, after "CCG" please insert ~~-(SEQ.I.D. NO. 15)-~~.

In table 1, page 38, line 14, after "R R" please insert ~~-(SEQ.I.D. NO. 16)-~~.

Please incorporate the enclosed nine pages of Sequence Listing after page 40, and renumber pages 50 through 52 accordingly.

IN THE CLAIMS:

1. (Amended) A peptide constituting a T-cell epitope obtainable from the minor Histocompatibility antigen HA-1, said peptide comprising the sequence VLXDDLLEA (SEQ.I.D. No. 1) or a derivative thereof having similar functional or immunological properties, wherein X represents a histidine or an arginine residue.

2. (Amended) An immunogenic polypeptide obtainable from the minor Histocompatibility antigen HA-1, said immunogenic polypeptide comprising the sequence VLXDDLLEA (SEQ.I.D. No. 1) or a derivative thereof having similar functional or immunological properties, wherein X represents a histidine or an arginine residue.

3. (Amended) [A peptide or]The immunogenic polypeptide [according to]of claim [1 or 2, comprising the sequence VLHDDLLEA]2, wherein X represents a histidine residue.

4. (Amended)[Vaccine]A vaccine comprising [an epitope or a]the immunogenic polypeptide [according to any one of claims 1-3]of claim 2.

5. (Amended) A pharmaceutical formulation comprising [an epitope or a]the immunogenic polypeptide [according to any one of claims 1-3]of claim 2.

Please cancel claim 6.

7. (Amended) [Use of a peptide or] A method of inducing tolerance for transplants to prevent rejection and/or Graft versus Host disease or to treat (auto)immune disease in a subject, said method comprising using, with said subject, the immunogenic polypeptide [according to claims 1-3 in the preparation of a medicament] of claim 2 for the induction of tolerance for transplants to prevent rejection and/or Graft versus Host disease or to treat (auto)immune disease.

8. (Amended) A method for the elimination of a group of (neoplastic) hematopoietic cells presenting a peptide or immunogenic polypeptide in the context of HLA class 1 [according to any of one of claims 1-3, whereby] of claim 2 wherein said elimination is induced directly [of] or indirectly by specific recognition of said [peptide] immunogenic polypeptide in said context.

9. (Amended) [Analog] An analog of [the peptide according to claim 1] a peptide constituting a T-cell epitope obtainable from the minor Histocompatibility antigen HA-1, said peptide comprising the sequence VLXDDLLEA (SEQ.I.D. No. 1) or a derivative thereof having similar functional or immunological properties, wherein X represents a histidine or an arginine residue, which analog is an antagonist for the activity of T cells recognizing said peptide.

10. (Amended) [Method] A process for [the generation of] producing antibodies, T cell receptors, anti-idiotypic B-cells or T-cells, said process comprising [the step of immunization of] immunizing a mammal with [a peptide or a] the immunogenic polypeptide [according to] of claim [1 or] 2, thus inducing production of said antibodies, T cell receptors, anti-idiotypic B-cells or T-cells in the mammal.

11. (Amended) Antibodies, T-cell receptors, B-cells or T-cells obtainable by the [method] process of claim 10.

12. (Amended) A [method] process for the [generation] production of a cytotoxic T-cell against a minor antigen, said process comprising:

contacting a hematopoietic cell[, preferably a dendritic cell with a peptide, preferably in the context of HLA class I, or a] with the immunogenic polypeptide [according to anyone]

of [claims 1-3]claim 2.

13. (Amended) [A method]The process according to claim 12, wherein said hematopoietic cell is negative for said minor antigen.

14. (Amended) [A method]The process according to claim 12 [or 13], wherein said minor antigen is HA-1.

15. (Amended) [A method]The process according to [any one of claims 12-14]claim 12 wherein said contacting of the hematopoietic cell with a peptide or an immunogenic polypeptide is carried out ex vivo.

16. (Amended) [A method]The process according to [any one of claims 12-15]claim 12, wherein said cytotoxic T-cell is provided with a suicide gene.

17. (Amended) [A method]The process according to [anyone of claims 12-16, whereby]claim 12 wherein said cytotoxic T-cell is immortalized.

18. (Amended) A cytotoxic T-cell or a derivative or an active fragment thereof, obtainable by [a method according to any one]the process of [claims 12-17]claim 12.


19. (Amended) [A]The cytotoxic T-cell [according to]of claim 18, which is capable of expansion.

### Remarks

The application is to be amended as previously set forth. All amendments, including claim cancellations, are made without prejudice or disclaimer. The amendments are made to bring the application closer to United States practice, such as, by example, removing multiple claim dependencies. It is respectfully submitted that no new matter has been added by the amendment.

If questions exist after consideration of the foregoing, the Office is kindly requested to contact the applicants' representative at the address or telephone number below.

Respectfully submitted,



Allen C. Turner  
Registration No. 33,041  
Attorney for Applicants  
TRASK, BRITT & ROSSA  
P. O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: (801) 532-1922

Date: January 21, 2000  
Enclosures: Sequence Listing  
Sequence Listing (CRF)  
Statement  
Abstract

N:\2183\4285\Preliminary amendment.wpd

Time	Temperature	Pressure	Humidity	Wind Speed	Wind Direction	Cloud Cover	Visibility	Soil Moisture	Leaf Wetness	Plant Growth	Animal Activity	Human Activity
08:00	25.0	1013.2	65%	1.2	135	10	10	15%	0.5	Low	Low	Low
09:00	26.5	1012.8	60%	1.5	140	15	10	20%	0.8	Low	Low	Low
10:00	28.0	1012.5	55%	1.8	145	20	10	25%	1.0	Low	Low	Low
11:00	29.5	1012.1	50%	2.0	150	25	10	30%	1.2	Low	Low	Low
12:00	31.0	1011.8	45%	2.2	155	30	10	35%	1.5	Low	Low	Low
13:00	32.5	1011.5	40%	2.5	160	35	10	40%	1.8	Low	Low	Low
14:00	34.0	1011.2	35%	2.8	165	40	10	45%	2.0	Low	Low	Low
15:00	35.5	1010.9	30%	3.0	170	45	10	50%	2.2	Low	Low	Low
16:00	37.0	1010.6	25%	3.2	175	50	10	55%	2.5	Low	Low	Low
17:00	38.5	1010.3	20%	3.5	180	55	10	60%	2.8	Low	Low	Low
18:00	40.0	1010.0	15%	3.8	185	60	10	65%	3.0	Low	Low	Low
19:00	41.5	1009.7	10%	4.0	190	65	10	70%	3.2	Low	Low	Low
20:00	43.0	1009.4	5%	4.2	195	70	10	75%	3.5	Low	Low	Low
21:00	44.5	1009.1	0%	4.5	200	75	10	80%	3.8	Low	Low	Low
22:00	46.0	1008.8	0%	4.8	205	80	10	85%	4.0	Low	Low	Low
23:00	47.5	1008.5	0%	5.0	210	85	10	90%	4.2	Low	Low	Low
00:00	49.0	1008.2	0%	5.2	215	90	10	95%	4.5	Low	Low	Low
01:00	50.5	1007.9	0%	5.5	220	95	10	100%	4.8	Low	Low	Low
02:00	52.0	1007.6	0%	5.8	225	100	10	100%	5.0	Low	Low	Low
03:00	53.5	1007.3	0%	6.0	230	100	10	100%	5.2	Low	Low	Low
04:00	55.0	1007.0	0%	6.2	235	100	10	100%	5.5	Low	Low	Low
05:00	56.5	1006.7	0%	6.5	240	100	10	100%	5.8	Low	Low	Low
06:00	58.0	1006.4	0%	6.8	245	100	10	100%	6.0	Low	Low	Low
07:00	59.5	1006.1	0%	7.0	250	100	10	100%	6.2	Low	Low	Low
08:00	61.0	1005.8	0%	7.2	255	100	10	100%	6.5	Low	Low	Low
09:00	62.5	1005.5	0%	7.5	260	100	10	100%	6.8	Low	Low	Low
10:00	64.0	1005.2	0%	7.8	265	100	10	100%	7.0	Low	Low	Low
11:00	65.5	1004.9	0%	8.0	270	100	10	100%	7.2	Low	Low	Low
12:00	67.0	1004.6	0%	8.2	275	100	10	100%	7.5	Low	Low	Low
13:00	68.5	1004.3	0%	8.5	280	100	10	100%	7.8	Low	Low	Low
14:00	70.0	1004.0	0%	8.8	285	100	10	100%	8.0	Low	Low	Low
15:00	71.5	1003.7	0%	9.0	290	100	10	100%	8.2	Low	Low	Low
16:00	73.0	1003.4	0%	9.2	295	100	10	100%	8.5	Low	Low	Low

Person making Deposit: Jared Turner

for

Inventors:  
Elsa A. J. M. Goulmy  
Donald F. Hunt  
Victor H. Engelhard

Attorney:  
Allen C. Turner  
Registration No. 33,041  
TRASK, BRITT & ROSSA  
P.O. Box 2550  
Salt Lake City, Utah 84110  
(801) 532-1922



WO 99/05173

PCT/NL98/00424

Title: The HA-1 antigen

The invention relates to the field of immunology, in particular to the field of cellular immunology.

Bone marrow transplantation (BMT), one of the areas the invention is concerned with and the area from which the present invention originates, finds its application in the treatment of for instance severe aplastic anaemia, leukaemia and immune deficiency diseases.

In the early days of this technique many transplants failed through rejection of the graft by the host. Transplants that did succeed, however often led to an immune response by lymphocytes present in the graft against various tissues of the host (Graft versus Host Disease (GvHD)). It is now known that the GvHD response is mainly due to the presence of major histocompatibility (H) antigens which present a

transplantation barrier. Therefore it is now routine practice to graft only HLA-matched materials (either from siblings or unrelated individuals) resulting in a much improved rate of success in bone marrow transplantation. However, despite this improvement, as well as improvements in pre-transplantation chemotherapy or radiotherapy and the availability of potent immuno-suppressive drugs, about 20-70% of the treated patients still suffer from GvHD (the percentage is age and bone marrow donor dependent). To avoid GvHD it has been suggested to remove the cells (mature T cells) causing said reaction from the graft. This however often leads to graft failure or to recurrence of the original disease. The cells responsible for GvHD are also the cells which often react against the original aberrant cells in for instance leukaemia (Graft versus Leukaemia response).

Since BMT is nowadays mainly carried out with HLA matched grafts, the GvHD which still occurs must be caused by another group of antigens. It is very likely that the group of so called minor H antigens (mHag), which are non-MHC encoded

WO 99/05173

PCT/NL98/00424

2

histocompatibility antigens (unlike the major H antigens) are at least partially responsible for the remaining incidence of GvHD. mHag's have originally been discovered in congenic strains of mice in tumor rejection and skin rejection studies. In mice, the use of inbred strains has shown that mHag are encoded by almost 50 different allelically polymorphic loci scattered throughout the genome. In humans, although cumbersome to identify, mHag have been shown to exist, but their overall number and complexity remains uncertain. Minor H antigens are most likely quite different from each other and quite different from major H antigens, they are probably a diverse and elusive group of fragments of molecules which are participating in various cellular housekeeping functions. Their antigenicity may come very incidentally, as naturally processed fragments of polymorphic proteins that associate with MHC products. Some of the mH antigens appear to be widely expressed on various tissues throughout the body whereas others show limited tissue distribution.

One of the better known minor histocompatibility antigens is the H-Y antigen. H-Y is an mH antigen that can lead to rejection of HLA-matched male organ and bone marrow grafts by female recipients, and to a higher incidence of GvHD in female-to-male grafts, particularly if the female donor had been previously pregnant. The H-Y antigen may also play a role in spermatogenesis. The human H-Y antigen is an 11 residue peptide derived from SMCY, an evolutionary conserved Y chromosomal protein. Another well known mH antigen that can lead to GvHD is the HA-2 antigen. The human HA-2 antigen is an 9 residue peptide likely derived from a class I myosin. However, the nature of the HA-1 antigen, responsible for a majority of current cases of GvHD has remained elusive sofar. Human bone marrow transplants performed as therapeutical treatment of severe aplastic anaemia, leukaemia and immune deficiency disease became available in the seventies. For the present, the long-term results of allogeneic bone marrow

00489750-0140

WO 99/05173

PCT/NL98/00424

3

transplantation (BMT) have greatly improved due to the use of HLA-matched siblings as marrow donors, advanced pretransplant chemoradiotherapy, the use of potent immunosuppressive drugs as Graft-versus-Host-Disease (GVHD) prophylaxis, better antibiotics and isolation procedures. Nonetheless, the results of clinical BMT reveal that the selection of MHC identical donors/recipients is not a guarantee of avoidance of GVHD or disease free survival even when donor and recipient are closely related. Allogeneic BMT especially in adults results, depending on the amount of T cell depletion of the graft, in up to 80% of the cases in GVHD. In the HLA genotypically identical situation it amounts to 15-35% whereas in the phenotypical HLA matched recipient/donor combinations, the occurrence of GVHD is significantly higher i.e. 50-80%. Disparities for minor Histocompatibility antigens (mHag) between donor and recipient constitute a potential risk for GVHD or graft failure, which necessitate life long pharmacologic immunosuppression of organ and bone marrow transplant recipients. It is also believed that mHag are involved in the "beneficial" side effect of GVHD i.e. the Graft-versus-Leukemia activity. Several reports demonstrated the presence of anti-host mHag specific CTL in patients suffering from GVHD after HLA genotypically identical BMT. In our laboratory, much effort was put into the further characterization of a (small) number of anti-host mHag specific CTLs. Hereto, CTL clones specific for host mHag were isolated from the peripheral blood (PBL) of patients suffering from severe GvHD. mHag HA-1 specific CD8<sup>+</sup> CTL clones were originally obtained after restimulation of in vivo primed PBLs from three patients suffering from GvHD after HLA identical but mHag nonidentical BMT. The post BMT CTL lines were cloned by limiting dilution, resulting in the isolation of a large number of mHag-specific CTL clones. Subsequent immunogenetic analyses revealed that the CTL clones (as described above) identified five non-sexlinked mHag, designated HA-1, -2, -3, -4, -5, which are recognized

WO 99/05173

PCT/NL98/00424

4

in a classical MHC restricted fashion. mHag HA-3 is recognized in the presence of HLA-A1 and mHag HA-1, -2, -4 and 5 require the presence of HLA-A2. Segregation studies demonstrated that each of mHag HA-1 to HA-5 is the product of a single gene segregating in a Mendelian fashion and that HA-1 and HA-2 are not coded within the HLA region. The mHag differ from each other in phenotype frequencies: mHag HA-1 appeared relatively frequent (i.e. 69%) whereas mHag HA-2 appeared very frequent (i.e. 95%) in the HLA-A2 positive healthy population. An inventory in five patients of mHag HA-1, -2, -3, -4 and -5 specific anti-host CTL responses after BMT demonstrated in 3 patients clones specific for the mHag HA-1. This observation points towards the immunodominant behaviour of mHag HA-1. With regard to the mHag expressed on different tissues, we observed ubiquitous versus restricted tissue distribution of the mHag analysed. The expression of the mHag HA-1 is restricted to the cells of the haematopoietic cell lineage, such as thymocytes, peripheral blood lymphocytes, B cells, monocytes. Also the bone marrow derived professional antigen presenting cells: the dendritic cells and the epidermal Langerhans cells express the mHag HA-1. The mHag HA-1 is also expressed on clonogenic leukemic precursor cells as well as on freshly isolated myeloid and lymphoid leukemic cells, indicating that mHag specific CTLs are capable of HLA class I restricted antigen specific lysis of leukemic cells. To substantiate the importance of the human mH antigenic systems, we investigated whether the mHag are conserved in evolution between human and non human primates. Hereto, cells from non human primates were transfected with the human HLAA2.1 gene. Subsequent analyses with our human allo HLA-A2.1 and four mHag A2.1 restricted CTL clones revealed the presentation of ape and monkey allo and mHag HY, HA-1 and HA-2 peptides in the context of the transfected human HLA-A2.1 molecule by ape and monkey target cells. This implicates that the HA-1 peptide is conserved for at least 35 million years. A prospective

WO 99/05173

PCT/NL98/00424

5

study was performed in order to document the effect and clinical relevance of mHag in HLA genotypically identical BMT on the occurrence of acute (grade  $\geq 2$ ) GVHD. The results of the mHag typing using the CTL clones specific for five well defined mHag HA-1 to HA-5 demonstrated a significant correlation between mHag HA-1, -2, -4 and -5 mismatch and GVHD. A significant correlation ( $P = 0.024$ ) with the development of GVHD was observed when analysed for only mHag HA-1. To analyse a putative peptidic nature of the mHag HA-1, we analysed the requirement of the MHC encoded TAP1 and TAP2 gene products for mHag peptide presentation on the cell surface. The transporter genes TAP1 and TAP2 associated with antigen presentation are required for delivery of peptides from the cytosol with the endoplasmic reticulum. The availability of a human cellline "T2" lacking both transport and proteasome subunit genes enabled us to study the processing and presentation of human mHag. We demonstrated that the (rat) transport gene products TAP1 and TAP2u were required for processing and presentation of antigenic peptides from the intracellular mH protein HA-1. Information on the TCR repertoire post BMT in man is extremely scarce. We have analysed the composition of the T cell receptor (TCR) V region of mHag HA-1 specific CD8+ CTL clones by DNA sequencing of the  $\alpha$  and  $\beta$  chains. We observed by analyzing TCR usage of 12 clones derived from 3 unrelated individuals that the TCR $\beta$  chains all used the TCR $\beta$ V6S9 gene segment and showed remarkable similarities within the N-D-N regions.

However, until the present invention no one has succeeded in identifying amino acid sequences of antigenic peptides relevant to the mHag HA-1 antigen, nor has anyone succeeded in the identification of the proteins from which this antigen is derived. We have now for the first time identified a peptide which is a relevant part of mHag HA-1.

Thus this invention provides a (poly)peptide comprising a T-cell epitope obtainable from the minor Histocompatibility antigen HA-1 comprising the sequence VLXDDLLEA or a

WO 99/05173

PCT/NL98/00424

6

derivative thereof having similar functional or immunological properties, wherein X represents a histidine (H) or an arginine (R) residue.

5 The way these sequences are obtained is described in the experimental part. An important part of this novel method of arriving at said sequences is the purification and the choice of the starting material. Said method is therefore also part of the scope of this invention. However, now that the sequence is known, it is of course no longer necessary to follow that method, because the peptides can easily be made synthetically, as is well known in the art. Since routine techniques are available for producing synthetic peptides, it is also within the skill of the art to arrive at analogs or derivatives of the explicitly described peptides, which analogs and/or derivatives may have the same or at least similar functional or immunological properties and or activity. On the other hand analogs which counteract the activity of the explicitly described peptides are also within the skill of the art, given the teaching of the present invention. Therefor derivatives and/or analogs, be it of the same or different length, be it agonist or antagonist, be it peptide-like or peptidomimetic, are part of the scope of this invention.

25 The invention provides a (poly) peptide which can be functionally presented to the immune system in the context of the HLA-A2.1 molecule. In general peptides presented in such a context vary in length from about 7 to about 15 amino acid residues, and a polypeptide can be enzymatically processed to a peptide of such length. A peptide provided by the invention typically is at least 7 amino acids in length but preferably at least 8 or 9 amino acids. The upper length of a peptide provided by the invention is no more than 15 amino acids, but preferably no more than about 13 or 11 amino acids in length. A peptide provided by the invention contains the necessary anchoring residues for presentation in the groove of the HLA-A2.1 molecule. An immunogenic polypeptide provided by the

WO 99/05173

PCT/NL98/00424

7

invention comprises a 7-15 amino acid long peptide, provided by the invention, optionally flanked by appropriate enzymatic cleavage sites allowing processing of the polypeptide. A preferred embodiment of the present invention is the

5 peptide with the sequence VLHDDLLEA which induces lysis of the cell presenting it at a very low concentration of peptide present. This does not imply that peptides inducing lysis at higher concentrations are not suitable. This will for a large part depend on the application and on other properties of the

10 peptides, which were not all testable within the scope of the present invention. The peptides and other molecules according to the invention find their utility in that they may be used to induce tolerance of the donor immune system in HA-1 negative donors, so that residual peripheral blood

15 lymphocytes in the eventually transplanted organ or the bone marrow, as it may be does not respond to host HA-1 material in a HA-1 positive recipient. In this way GvHD will be prevented or mitigated. On the other hand tolerance can be induced in HA-1 negative recipients in basically the same

20 way, so that upon receipt of an organ or bone marrow from an HA-1 positive donor no rejection on the basis of the HA-1 material occurs. For tolerance induction very small doses can be given repeatedly, for instance intravenously, but other routes of administration may very well be suitable too.

25 Another possibility is the repeated oral administration of high doses of the peptides. The peptides may be given alone, or in combination with other peptides, or as part of larger molecules, or coupled to carrier materials in any suitable excipients. Further applications of the peptide or

30 derivatives thereof lie in the prophylactic administration of such to transplanted individuals to prevent GvHD. This can be done with either agonists, possibly in combination with an adjuvant, or with antagonists which may block the responsible cells. This can be done with or without the concomittant

35 administration of TCR derived peptide sequences or of cytokines. Furthermore the peptides according to the

WO 99/05173

PCT/NL98/00424

8

invention can be used to prepare therapeutic agents capable of eliminating a subset of cells, directly or indirectly, especially cells of hematopoietic origin. This can be illustrated by the following examples, which refer to leukemia related therapeutic agents.

A HA-1 positive recipient (in bone marrow transplantation) can be subjected to an additional pre-bone marrow transplant conditioning regime. This means that an agent which specifically recognizes a peptide according to the invention (a HA-1 peptide) as presented selectively on hematopoietic cells, which agent induces elimination of the cells presenting said peptide, is administered to the recipient before transplantation. This agent will eliminate all residual cells (leukemic cells) of hematopoietic origin. Such agents include but are not limited to T cells (which are tailor made ex vivo by pulsing with the peptides provided by the invention, and optionally provided with a suicide gene) and/or antibodies coupled to toxic moieties.

A HA-1 negative donor for bone marrow transplantation can be vaccinated with a peptide according to the invention, a HA-1 peptide. Upon transplantation to a HA-1 positive recipient, the donor's immune system can eliminate any residual or recurrent HA-1 peptide presenting cells in the recipient which are of course leukemic. This is another example of tailor-made adoptive immunotherapy provided by the invention. A transplanted HA-1 positive recipient, transplanted with HA-1 negative (or for that matter HA-1 positive) bone marrow and suffering from recurrent disease (relapse), i.e. HA-1 positive leukemic cells, can be treated with (again) an agent (as above) which specifically recognizes a peptide according to the invention (a HA-1 peptide) as presented on hematopoietic cells, which agent induces elimination of the cells presenting said peptide. In case of HA-1 positive bone marrow being transplanted to the HA-1 positive recipient, it is still essential (in case of recurrent disease) to eliminate all HA-1 positive cells even though this includes



WO 99/05173

PCT/NL98/00424

9

the transplanted material, because otherwise the HA-1 positive leukemia will kill the recipient. To avoid the latter case the patient can be re-transplanted, if necessary. In such therapy protocols it is possible to first employ adoptive immunotherapy with agents (cells, antibodies, etc.) which specifically recognize and eliminate specific peptide expressing cells (e.g. leukemic cells) that need to be destroyed, after which in a second phase the patient is reconstituted with BMT cells replacing the killed cells. The invention thus provides additional (or even substituting) protocols to other therapeutic measures such as radiation.

Other therapeutical applications of the peptide include the induction of tolerance to HA-1 proteins in HA-1 related (auto)immune diseases. On the other hand they may be used in vaccines in HA-1 related (auto)immune diseases.

Diagnostic applications are clearly within the skill of the art. They include, but are not limited to HA-1 typing, detection of genetic aberrances and the like. Specific gene sequences can be detected with various methods known in the art, such as hybridization or amplification with PCR and the like. Immunological detection of peptides has also widely been practiced.

On the basis of the peptide described herein genetic probes or primers can be produced which can be used to screen for the gene encoding the protein. On the other hand such probes will be useful in detection kits as well. On the basis of the peptide described herein anti-idiotypic B cells and/or T cells and antibodies are produced. Various techniques, to allow detection of suitable donors or recipients, may be used, based on amplification of HA-1 related nucleic acid sequences or on the immunological detection of HA-1 related peptide sequences. Suitable amplification or detection techniques are known in the art, and the invention enables the production of diagnostic test kits for HA-1 allelic detection and typing. The GVHD associated mH antigen HA-1 is a peptide derived from one protein allele of a di-allelic

WO 99/05173

PCT/NL98/00424

10

genetic system. The identification of this mH antigen HA-1 enables prospective HA-1 typing of BMT donors and recipients to improve donor selection and thereby prevention of GVHD induction. All these embodiments have been made possible by the present disclosure and therefor are part of the present invention. The techniques to produce these embodiments are all within the skill of the art.

Furthermore, the identification of the HA-1 antigen allows the production of synthetic HA-1 peptides and peptides functionally and/or immunologically related thereto. Such peptides (which can include left or right turning residues) are designed and/or generated by various methods known in the art such as peptide synthesis and replacement mapping, followed by functional binding studies. Altered peptide ligands (APL) for the HLA-A2.1 restricted HA-1 epitope enable modification of the HA-1 directed T cell responses and thus modulate and/or mitigate the GvHD associated T cell response. In general, T cells are activated by the interaction of the T cell receptor (TCR) with the antigenic peptide in the context of a MHC molecule and can react with a number of different effector functions. APL can interact with the TCR and change the effector functions of the T cell qualitatively and/or quantitatively. APL, used in vitro as well as *ex vivo* can act as antagonist or agonist for the TCR and can anergize the T cells specific for the wild type peptide. The HA-1 peptide is used to induce tolerance in the living bone marrow or organ (kidney, liver, gut, skin, etc.) of HA-1 negative donors for HA-1 positive patients,. In bone marrow transplantation, the peptide (given alone or in combination with others) is used to induce tolerance in the living bone marrow donor. The peptide(s) may be given orally, intravenously, intra-ocularly, intranasally or otherwise. In all forms of organ, tissue and bone marrow transplantation, the HA-1 peptide is used to induce tolerance in HA-1 negative recipients.

WO 99/05173

PCT/NL98/00424

11

The invention also provides an analog of the peptide according to the invention which is an antagonist for the activity of T cells recognizing the peptide. Such an analog is obtained using methods and tests known in the art.

- 5 Furthermore, the invention provides a method for the generation of antibodies, T cell receptors, anti-idiotypic B-cells or T-cells, comprising the step of immunization of a mammal with a peptide or a polypeptide according to the invention, and the antibodies, T-cell receptors, B-cells or  
10 T-cells obtainable by the method. Dose ranges of peptides and antibodies and/or other molecules according to the invention to be used in the therapeutical applications as described herein before are designed on the basis of rising dose studies in the clinic in clinical trials for which  
15 rigorous protocol requirements exist.

- An important advantage of using mHag-specific CTLs in adoptive immunotherapy of for example leukemia lies in their restricted and specific target cell damage. We take advantage of three of the known characteristics of human mHag  
20 i.e. 1) MHC-restricted recognition by T cells; 2) variable phenotype frequencies, i.e. mHag polymorphism; and 3) restricted tissue distribution, allowing specific and distinct targeting of mHag HA-1 related therapy. Restrictive HA-1 tissue expression significantly increases the success of  
25 adoptive immunotherapy towards various types of cancer, such as small cell lung carcinoma cells which express also the HA-1 antigen. Moreover, since mHag are clearly expressed on circulating leukemic cells and clonogenic leukemic precursor cells of both myeloid and lymphoid origin, both types of  
30 leukemias can be targeted. mHag peptide CTLs can be generated ex vivo from mHag-negative BM donors for mHag-positive patients. Peptide-specific CTL clones from an HLA-A1-positive mHag-negative healthy blood donor are generated by pulsing autologous APCs with mHag HA-1 related synthetic peptide.  
35 Proliferating clones are expanded and tested for specific cytotoxic activity. Upon transfusion (either pre-BMT as part

WO 99/05173

PCT/NL98/00424

12

of the conditioning regimen or post-BMT as adjuvant therapy), the mHag peptide-specific CTLs will eliminate the mHag-positive patient's leukemic cells and, if of the patient's origin, also the patient's hematopoietic cells but will spare the patient's non-hematopoietic cells. If necessary, subsequent mHag-negative donor BMT will restore the patient's hematopoietic system. A universal approach is to generate "prefab" mHag peptide-specific CTLs by using mHag-negative healthy blood donors with frequent HLA-homozygous haplotypes. Patients who are mHag-positive (and their BM donors mHag-negative) and who match the HLA typing of the CTL donor can be treated with these "ready to be used" allo-peptide specific CTLs. Transduction of these CTLs with a suicide gene allows elimination of the CTLs in case adverse effects occur. For the sake of illustration a number of methods and applications is also given below in the experimental part.

#### Experimental part.

Graft-versus-Host Disease (GvHD) is a frequent and life-threatening complication after allogeneic HLA-identical bone marrow transplantation (BMT). Recipients of HLA-identical bone marrow develop acute or chronic Graft-versus-Host-Disease in respectively 36% and 49%<sup>1,2</sup>. Disparities in genes other than the MHC, referred to as minor histocompatibility (mH) antigens, are clearly involved in the development of GvHD after HLA-identical BMT. A recent retrospective analysis revealed the significant association between mismatching for the mH antigen HA-1 and the induction of GvHD after HLA-identical BMT<sup>3</sup>. Minor histocompatibility antigens are recognized by MHC restricted T cells and were shown to be peptides derived from intracellular proteins presented by MHC molecules<sup>4-6</sup>. Here we report the first identification of a polymorphic gene encoding an human mH antigen. The GvHD associated mH antigen HA-1 is a nonapeptide derived from the di-allelic KIAA0223 gene. The HA-1 allelic counterpart

WO 99/05173

PCT/NL98/00424

13

encoded by the KIAA0223 gene differs only at one amino acid from the mH antigen HA-1. Family studies demonstrated an exact correlation between the KIAA0223 gene polymorphism and the HA-1 phenotype as was previously determined by  
5 recognition by the HA-1 specific CTL clones. The elucidation of the HA-1 encoding gene enables prospective HA-1 DNA typing of BMT donors and recipients to improve donor selection and prevention of GvHD.

Cytotoxic T cell clones specific for the mH antigen HA-1 have  
10 been isolated from three different patients with severe GvHD<sup>7</sup>. The mH antigen HA-1 is presented in the context of HLA-A2.1 and present in 69% of the HLA-A2.1 positive population<sup>7</sup>. HA-1 expression was demonstrated to be tissue specific and limited to cells of haematopoietic origin, including  
15 dendritic cells, Langerhans cells and leukemic cells<sup>8-10</sup>. Family analysis indicated a mendelian mode of inheritance for HA-1 and segregation independent from the MHC complex<sup>11</sup>. Comparison of the T cell receptor (TCR) sequences of different HA-1 specific T cell clones derived from different  
20 individuals revealed conserved usage of the TCR Vb6.9 and conserved amino acids in the CDR3 region<sup>12</sup>. In a retrospective study, mismatching for a number of mH antigens was evaluated with regard to the association with GvHD after HLA-identical BMT. A single HA-1 mismatch between donor and  
25 recipient was significantly correlated with the induction of GvHD after HLA-identical BMT<sup>3</sup>.

To identify the mH antigen HA-1, HLA-A2.1 molecules were purified from two HA-1 expressing EBV-transformed B lymphoblastoid cell lines (EBV-BLCL) Rp and Blk. The HLA-A2.1  
30 bound peptides were isolated by acid treatment and fractionation of the peptides was performed by multiple rounds of reverse phase HPLC. The fractions were analysed for their capacity of inducing HA-1 specific lysis using T2 cells as target cells and an HA-1 specific CTL clone as effector  
35 cells in a <sup>51</sup>Cr-release assay (Fig 1a). Fraction 24 contained HA-1 activity and was two times further fractionated with

reverse phase HPLC using a different organic modifier (Fig 1b.c.). Fraction 33 and 34 of the third HPLC fractionation showed HA-1 activity <sup>51</sup>Cr-release assay and were analysed by tandem mass spectrometry. Because over a 100 different peptides were present in these fractions, around 40% of fractions 33 and 34 was chromatographed with an on-line microcapillary column effluent splitter. The fractions were simultaneously analysed by tandem mass spectrometry and <sup>51</sup>Cr-release assay (Fig 1d.). Five peptide species (at m/z 550, 520, 513, 585 and 502) were specifically present in active fractions and absent in fractions without activity in the CML assay. Collision activated dissociation analysis of peptide candidate m/z 550 revealed the sequence YXTDRVMTV. X stands for Isoleucine or leucine that cannot be discriminated with this type of mass spectrometer. However, a synthetic peptide with this sequence was not able to reconstitute the HA-1 epitope (results not shown). To determine which of the four remaining candidates was the HA-1 peptide the second HA-1 purification of the EBV-BLCL Blk was evaluated. HA-1 positive peptide fraction 33 of the second reverse phase HPLC fractionation was further chromatographed by microcapillary HPLC with a third organic modifier. A single peak of reconstituting activity was observed in a <sup>51</sup>Cr-release assay (results not shown). Mass spectral analysis of these fractions revealed that only peptide candidate m/z 513 was present. This peptide was analyzed with collision activated dissociation analysis and sequenced as VXHDDXXEA (Fig 2a). Isoleucine and Leucine variants of the peptide were synthesized and run on the microcapillary HPLC column. Only peptide VLHDDLLEA coeluted with the naturally processed peptide 513 (results not shown). Next, synthetic VLHDDLLEA added in different concentration to a CML assay with 3 different HA-1 specific CTL clones revealed recognition by all three clones of the peptide with a half maximal activity at 150-200 pM for or all three clones (Fig 2b). This

demonstrated that the mH antigen HA-1 is represented by the nonapeptide VLHDDLLEA.

Database searches performed to identify the gene encoding HA-1, revealed that the HA-1 peptide VLHDDLLEA was identical for 8 out of 9 amino acids with the peptide VLRDDLLEA from the KIAA0223 partial complementary DNA (cDNA) sequence, derived from the acute myelogenous leukemia KG-1 cellline. Because HA-1 has a population frequency of 69%, we reasoned that the VLRDDLLEA peptide sequence might represent the HA-1 allelic counterpart present in the remaining 31% of the population. To elaborate on this assumption, we performed cDNA sequence analysis of the putative HA-1 encoding region of KIAA0223 in EBV-BLCL derived from a presumed HA-1 homozygous positive (vR), from a presumed HA-1 negative individual (DH) and from the KG-1 cell line (Table 1.). The HA-1 encoding region of KIAA0223 of the HA-1+/+ individual (vR) displayed two nucleotides differences from the KIAA0223 sequence in the databank, leading to the amino acid sequence VLHDDLLEA (designated HA-1<sup>H</sup>). The HA-1 encoding region of KIAA0223 of the HA-1-/- individual (DH) showed 100% homology with the reported KIAA0223 sequence (designated HA-1<sup>R</sup>). The KG-1 cell line expressed both KIAA0223 alleles. Because KG-1 does not express the restriction molecule HLA-A2.1 necessary for T cell recognition, we transfected KG-1 with HLA-A2.1 and used these cells as target cells in a <sup>51</sup>Cr-release assay with the HA-1 specific T cell clone as effector cells. According to the cDNA sequence analysis results, the KG-1 cells were recognized by the HA-1 specific T cell clone (data not shown). This result suggested that the KIAA0223 gene forms a di-allelic system of which the HA-1<sup>H</sup> allele leads to recognition by the mH antigen HA-1 specific T cell clones. Two families, who were previously typed for HA-1 with HA-1 specific CTL, were studied on the cDNA level for their KIAA0223 polymorphism. The family members of family 1. were screened for their KIAA0223 sequence polymorphism by sequencing the HA-1 encoding sequence region. All HA-1

negative members displayed the HA-1<sup>R</sup> sequence, whereas all HA-1 positive members turned out to be heterozygous, thus carrying both HA-1 alleles (Fig3a). We subsequently designed HA-1 allele specific PCR primers to screen another family

5 previously cellularly typed for HA-1. Both parents and one child were determined as heterozygous for HA-1, two HA-1 negative children homozygous for the HA-1<sup>R</sup> allele and one child homozygous for the HA-1<sup>H</sup> allele (Fig.3b). The screening of both families showed an exact correlation of the HA-1

10 phenotype as determined by recognition by the HA-1 specific T cell clones and the KIAA0223 gene polymorphism. To definitely prove that the KIAA0223 gene encodes the mH antigen HA-1, the HA-1 encoding sequence region of KIAA0223 of both the HA-1<sup>H</sup> and the HA-1<sup>R</sup> alleles were cloned in a

15 eukaryotic expression vector and transiently transfected in HA-1 negative Hela cells in combination with HLA-A2.1. HA-1 specific T cell recognition of these transfected Hela cells was assayed using a TNFa release assay. The Hela cells transfected with the HA-1<sup>H</sup> sequence containing vector were

20 recognized by two HA-1 specific T cell clones (Fig.3c). In contrast transfection of the HA-1<sup>R</sup> sequence containing vector did not lead to recognition. In conclusion, our results clearly demonstrate that the mH antigen HA-1 is encoded by the HA-1<sup>H</sup> allele of the KIAA023 gene.

25 Reconstitution and HLA-A2.1 binding assays were performed to determine the capacity of HA-1<sup>R</sup> peptide VLRDDLLEA to bind to HLA-A2.1 and to be recognized by the HA-1 specific T cell clones. The concentration of the HA-1<sup>R</sup> peptide that inhibited the binding of a fluorescent standard peptide to HLA-A2.1 by

30 50 % (IC50) was 365 nM, falling in the intermediate binders, whereas the IC50 of the HA-1<sup>H</sup> peptide was 30 nM, which is in the range of high affinity binders (Fig. 4a) <sup>13,14</sup>. Different concentrations of VLRDDLLEA were tested in a <sup>51</sup>Cr-release assay with three HA-1 specific T cell clones. One out of

35 three clones (3HA15) tested showed recognition of the HA-1<sup>R</sup> peptide, but only at 1000 times higher peptide concentration



than that necessary for the recognition of the HA-1<sup>H</sup> peptide (Fig 4b). As the binding affinity of the two peptides to HLA-A2.1 differs only 10-fold, it can be concluded that all the T cell clones specifically recognize the HA-1<sup>H</sup> peptide.

- 5 The 3HA15 T cell clone, recognizing the HA-1<sup>R</sup> peptide at high concentrations, does not recognize HA-1<sup>R</sup> homozygous individuals. This suggests that the VLRDDLLEA peptide is not presented by HLA-A2.1 or presented below the detection limit of the T cell. To determine whether the HA-1<sup>R</sup> peptide
- 10 VLRDDLLEA was presented by HLA-A2.1, HLA-A2.1 bound peptides were eluted from a HA-1<sup>R</sup> homozygous EBV-BLCL and fractionated with reverse phase HPLC. The synthetic HA-1- peptide VLRDDLLEA was run on reverse HPLC to determine at which fraction this peptide eluted. The corresponding HPLC
- 15 fractions derived from the HA-1<sup>R</sup> expressing EBV-BLCL were analysed using mass spectrometry. Presence of peptide VLRDDLLEA could not be detected (results not shown), indicating that this peptide is not or in very low amounts presented by HLA-A2.1 on the cell surface. This is most
- 20 likely due to the 10-fold lower binding affinity of the peptide for HLA-A2.1. The supposed absence of the HA-1<sup>R</sup> peptide in HLA-A2.1 indicate that this allele must be considered as a null allele with regard to T cell reactivity. This implicates that only BMT from an HA-1<sup>R/R</sup> (HA-1-) donor to
- 25 HA-1<sup>H/H</sup> or HA-1<sup>R/H</sup> (HA-1+) recipient direction and not the reverse would be significantly associated with GvHD. This is indeed observed in a retrospective study in which HLA-A2.1 positive BMT pairs were typed for HA-1<sup>3</sup>. However, HA-1<sup>R</sup> derived peptides may bind to other HLA alleles and possibly
- 30 be recognized by T cells. If the latter peptides are not generated and presented by the HA-1<sup>H</sup> allele, then T cell reactivity towards the HA-1<sup>R</sup> allele may be envisaged and GvHD in that direction may occur.

- Only a few murine and human mH antigens have been identified
- 35 so far on the peptide and gene level. Two murine mH antigens are encoded by mitochondrial proteins, leading to respectively

four and two alleles <sup>15-17</sup>. In addition, two murine H-Y mH antigens were shown to be peptides encoded by Y-chromosome located genes <sup>18-21</sup>. The human *SMCY* gene, located on the Y chromosome, encodes the HLA-B7 and the HLA-A2.1 restricted H-Y mH antigens <sup>5,6</sup>. Of the human non-sex linked mH antigens only the mH antigen HA-2 has been sequenced on the peptide level, but the HA-2 encoding gene remained unknown <sup>4</sup>. The identification of the gene encoding the mH antigen HA-1 is the first demonstration that human mH antigens are derived from polymorphic genes. The HA-1 encoding KIAA0223 gene has two alleles differing in two nucleotides leading to one single amino acid difference. However, because the KIAA0223 gene has not been fully sequenced yet, it remains to be established whether additional amino acid polymorphisms between the two alleles of this gene are present. Because the HA-1 mH antigen is the only known human mH antigen that is correlated with the development of GvHD after BMT the results of our study are of significant clinical relevance <sup>3</sup>. Although the numbers of different human mH antigens is probably high, it is envisaged that only few immunodominant mH antigens can account for the risk for GvHD <sup>22</sup>. Identification of those human immunodominant mH antigens and screening for those antigens may result in a significant decrease in GvHD after BMT. Here we describe the first elucidation of a polymorphic gene encoding the immunodominant mH antigen HA-1. This enabled us to design HA-1 allele specific PCR primers for pre-transplant donor and recipient typing to improve donor selection and thereby prevention of HA-1 induced GvHD development. It also enabled us to start targeting leukemic cells carrying minor antigens present on hematopoietic cells. One way of arriving at agents targetting leukemic cells, is the ex vivo preparation of CTL's. This is explained herein below. Allogeneic bone marrow transplantation (BMT) is a common treatment of hematological malignancies <sup>29</sup>. Recurrence of the underlying malignancy is a major cause of treatment failure

30,31. Relapsed CML patients can be successfully treated by donor lymphocyte infusions (DLI) <sup>32, 33</sup>, but the treatment is less effective for relapsed AML and ALL<sup>32, 33</sup>, and is frequently complicated with Graft versus Host Disease (GvHD)

5 <sup>32-34</sup>. Donor derived CTLs specific for patients' minor histocompatibility antigens (mHags) play an important role in both GvHD and GvL reactivities <sup>10, 35-38</sup>. mHags HA-1 and HA-2 induce HLA-A2 restricted CTLs in vivo. mHags HA-1 and HA-2 are exclusively expressed on hematopoietic cells including

10 leukemic cells <sup>10, 36</sup> and leukemic precursors<sup>37, 38</sup>, but not on cells of the GvHD target organs such as skin fibroblasts, keratinocytes or liver cells <sup>8</sup>. Recently the chemical nature of the mHags HA-1 and HA-2 was unraveled <sup>4, 39</sup>. Here we report on the feasibility of ex-vivo generation of mHag HA-1 and HA-

15 2 specific CTLs from unprimed mHag HA-1 and/or HA-2 negative healthy blood donors with the purpose of adoptive immunotherapy of relapsed leukemia with a low risk of GvHD. To define the optimal antigen presenting cell (APC) for ex vivo generation of HA-1 and HA-2 specific CTLs, we prepared

20 peripheral blood mononuclear cells (PBMC), monocytes, peripheral blood circulating dendritic cells (PBDC) or dendritic cells derived from bone marrow CD34+ progenitor cells (BMDC) from fifteen HLA-A2 positive, HA-1 or HA-2 negative healthy blood donors. These APCs were pulsed with

25 HA-1 and/or HA-2 synthetic peptides and used to stimulate autologous unprimed CD8<sup>+</sup> T cells. The attempts to induce HA-1 or HA-2 specific CTLs using monocytes or PBMC were not very successful. PBMC induced in only one out of three attempts HA-2 specific CTLs. Using monocytes, we generated two HA-1

30 peptide specific CTLs, but these CTLs did not lyse HA-1 positive target cells in our experiments (data not shown). It is possible that these "peptide specific" CTLs have a lower affinity for the naturally expressed HA-1 antigen, but this does not mean that these cells can not be used for generating

35 CTL's against minor antigens.

PBDC were enriched from nine individuals to induce HA-1 or HA-2 specific CTLs. In the four cases where the preparations had a purity of less than 30 % the CTLs lysed peptide loaded target cells but not mHag positive target cells (data not shown). In contrast, in all cases (n=5) where PBDC purity was 30% or more, the CTLs not only recognized mHag negative, peptide pulsed target cells, but also mHag positive EBV-LCL, demonstrating the recognition of the naturally expressed ligand (figure 1). These results underscore the superior capacity of DC to induce T cell responses from naive precursors and confirm the current opinion<sup>40</sup>. Similarly, two BMDC induced CTLs that recognized both peptide pulsed target cells and HA-1 positive target cells (figure 5). No cytotoxic activity was observed against autologous PHA stimulated T cell blasts (PHA blasts) or against mHag negative EBV-LCL. Thus, neither autoreactivity nor "third-party" alloantigen reactivity was observed. Several HA-1 or HA-2 specific CTL clones isolated from these CTLs did not react against autologous cells either. These results show that HA-1 and HA-2 specific CTLs can be safely transferred to patients after BMT.

The ex-vivo induced HA-1 and HA-2 specific CTLs were tested for their hematopoietic cell restricted reactivity and compared with the in vivo induced HA-1 and HA-2 specific CTLs (figure 6). PHA blasts, but not fibroblasts (neither after IFN-g /TNF-a stimulation) were recognized by both ex-vivo and in vivo induced HA-1 and HA-2 specific CTLs. Fibroblasts, were only lysed after pulsing with the mHag peptides, demonstrating their susceptibility to CTL mediated lysis. These data not only confirm that the HA-1 and HA-2 antigens are functionally expressed solely on hematopoietic cells<sup>8</sup>, but also show that adoptive transfer of HA-1 or HA-2 specific CTLs to HA-1 or HA-2 positive patients will spare the patient's non-hematopoietic tissues and cells. Thus, upon adoptive transfer of HA-1 and HA-2 specific CTLs, a low risk of GvHD is to be expected. Some precaution may be necessary

since we have previously demonstrated that HA-1 disparity between patient and donor is associated with the development of GvHD in adults<sup>3</sup>. Therefore we transfer the CTLs not before 50-60 days post BMT. It is assumed that most recipient hematopoietic cells are then be replaced by donor cells. Alternatively, one may transduce the HA-1 and HA-2 specific CTLs with a suicide gene which will make the in vivo elimination of cells possible if adverse effects occur <sup>41</sup>. The ex-vivo induced HA-1 and HA-2 specific CTLs were subsequently analyzed for cytolytic activity against, for this study most relevant target cells, leukemic cells. In vivo induced HA-1 and HA-2 specific CTLs and an HLA-A2 specific alloreactive CTL were used as control effector cells. As shown in figure 7, AML and ALL cells were lysed by HLA-A2 specific alloreactive CTL, and by in vivo induced HA-1 and HA-2 specific CTLs, indicating that the leukemic cells were positive for HLA-A2 and expressed HA-1 or HA-2 antigens. As expected the ex-vivo induced CTLs lysed the leukemic cells comparable to the control effector cells. These results show that HA-1 and HA-2 specific CTLs can also be used as therapy for relapsed AML or ALL, which are resistant to DLI treatment. The level of cytotoxicity could be significantly enhanced following IFN-g and TNF-a treatment of the leukemic cells indicating that cytokines upregulated HLA class I expression on the leukemic cells. HA-1 and HA-2 specific CTL clones produce IFN-g and TNF-a ex vivo. It is possible that cytokine production by HA-1 and HA-2 specific CTLs occurs in vivo as well. Alternatively the efficacy of adoptive immunotherapy with HA-1 and HA-2 specific CTLs may be enhanced by co-administration of IFN-a in resistant cases. The feasibility of adoptive immunotherapy with ex-vivo generated CTLs depends also on their expandability to sufficient numbers. We therefore scored the expansion rates of HA-1 and HA-2 specific CTLs generated by DC. The results indicate that sufficient numbers of CTLs for adoptive immunotherapy can be obtained if T cell cultures will be

started with  $5 \times 10^7$  responder cells. For instance two HA-2 specific CTLs induced by PBDC showed expansion rates of above 9, 25 and 8 fold at the second, third, and fourth week, respectively. These expansion rates translate into an estimated total yield of  $3 \times 10^9 - 10^{10}$  CTLs at the end of the fourth week. The expansion kinetics of the HA-1 specific CTLs were slower, but the cells expanded consistently with doubling times of 2-3 days during each restimulation. It is estimated that  $10^9$  HA-1 specific CTLs can be obtained after five weeks of culture.

In conclusion our results show for the first time that mHag HA-1 and HA-2 specific CTLs can reproducibly be generated ex-vivo from HLA-A2 positive, mHag HA-1 and/or HA-2 negative healthy blood donors using dendritic cells pulsed with synthetic peptides. After the successful application of EBV-specific CTLs as specific adoptive immunotherapy of EBV-related malignancies<sup>42</sup>, our results now provide a new possibility for the treatment of relapsed, HA-1 and/or HA-2 positive leukemia patients with HA-1 or HA-2 specific CTLs induced ex-vivo from their HLA identical, mHag negative bone marrow donors.

### Methods

**Cell culture.** The CD8+ HLA-A2.1 restricted HA-1 specific cytotoxic T cell clones 3HA15, clone 15 and 5W38 were derived from PBMC of two patients who had undergone HLA identical bone marrow transplantation<sup>7,23</sup>. The clones were cultured by weekly stimulation with irradiated allogeneic PBMC and BLCL in RPMI-1640 medium containing 15 % human serum, 3 mM l-glutamin, 1% Leucoagglutinin-A and 20 U/ml rIL-2. The HLA-A2.1 positive HA-1 expressing EBV transformed B cell lines (BLCL) Rp and Blk were maintained in IMDM containing 5% FCS. The KG-1 and T2 cell lines were cultured in 1640 medium containing 3 mM l-glutamin and 10% FCS.

**<sup>51</sup>Cr-release assay.** HPLC fractions and synthetic peptides were tested in a <sup>51</sup>Cr-release assay as described <sup>24</sup>. 2500 <sup>51</sup>Cr labeled T2 cells in 25 ml were incubated with 25 ml peptide dissolved in Hanks 50mM Hepes for 30 minutes at 37°C.

- 5 Cytotoxic T cells were added in an endvolume of 150 ml. When HPLC peptide fractions were tested, T2 was incubated with 2 mg/ml MA2.1 during the <sup>51</sup>Cr labelling. After 4 hours at 37°C the supernatants were harvested.

- Peptide purification.** Peptides were eluted out of purified HLA-A2.1 molecules as earlier described <sup>24</sup>. Briefly, HLA-A2.1 molecules were purified two times from 90.10<sup>9</sup> HLA-A2.1 positive EBV-BLCL by affinity chromatography with BB7.2 coupled CNBR-activated sepharose 4B beads (Pharmacia LKB) and extensively washed. Peptides were eluted from the HLA-A2.1 with treatment with 10% acetic acid, further acidified by 1% TFA and separated from the HLA-A2.1 heavy chain and b2-microglobulin by filtration over a 10kD Centricon (Amicon) filter. Peptides were fractionated using reverse phase micro HPLC (Smart System, Pharmacia). For the first purification three rounds of HPLC fractionation were used to purify the HLA-A2.1 restricted HA-1 active peptide fractions from 90.10<sup>9</sup> Rp cells. The first fractionation consisted of buffer A: 0.1% HFBA in H<sub>2</sub>O, buffer B: 0.1% HFBA in acetonitrile. The gradient was 100% buffer A (0 to 20 min), 0 to 15% buffer B (20 to 25 min) and 15 to 70% buffer B (25 to 80 min) at a flow rate of 100 ml/min. Fractions of 100 ml were collected. Fraction 24 of the first gradient was further fractionated. The second fractionation consisted of buffer A: 0.1% TFA in H<sub>2</sub>O, buffer B: 0.1% TFA in acetonitrile. The gradient was 100% buffer A (0 to 20 min), 0 to 12% buffer B (20 to 25 min), and 12 to 50 % buffer B (25 to 80 min) at a flow rate of 100 ml/min. Fractions of 100 ml were collected. A shallower third gradient was used to further purify fraction 27 that contained HA-1 activity. The gradient was 100% buffer A (0 to 29 min), 0 to 18% buffer B (29 to 34 min), 18% buffer B (34 to 39 min), 18 to 23.9 % buffer B (39 to 98 min) at a

flowrate of 100 ml/min. 1/180 to 1/45 of the starting material was used to test for positive fractions in the  $^{51}\text{Cr}$ -release assay. Comparable HPLC fractionations were used for the second purification of HLA-A2.1 restricted HA-1 active peptide fractions from 90.10<sup>9</sup> Blk. 40% of the HA-1 containing fraction 33 of the second HA-1 purification was used for an additional reverse phase microcapillary HPLC fractionation. Buffer A was 0.1% triethyl amine (TEA) in water buffered to pH 6.0 with acetic acid and buffer B was 0.085% TEA in 60% acetonitrile buffered to pH 6.0 with acetic acid. The gradient was 100% buffer A (0 to 5 min), 0 to 100% B (5 to 45 min) at a flow rate of 0.5 ml/min. Fractions were collected in 50 ml of 0.1% acetic acid every minute for 5 to 15 minutes, every 30 seconds from 15 to 20 minutes, every 20 seconds from 20 to 40 minutes, and every 30 seconds from 40 to 45 minutes. For each fraction collected, 20% was used to test for HA-1 activity and 80% was used to obtain mass spectral data.

**Mass spectrometry.** Fractions from third dimension HPLC separation of the Rp purification that contained the HA-1 activity were analyzed by microcapillary HPLC-electrospray ionization mass spectrometry <sup>25</sup>. Peptides were loaded onto a C18 microcapillary column (75mm i.d. x 10 cm) and eluted with a 34 minute gradient of 0 to 60% B, where solvent A was 0.1M acetic acid in water and solvent B was acetonitrile at a flow-rate of 0.5ml/min. One-fifth of the effluent was deposited into the wells of a 96-well plate containing 100 ml of culture media in each well (10 seconds fractions), while the remaining four-fifths was directed into the elctrospray source of the TSQ-70U. Mass spectra and CAD mass spectra were recorded on a Finnigan-MAT TSQ-7000 (San Jose, California) triple quadrupole mass spectrometer equipped with an electrospray ion source.

**HLA-A2.1 peptide binding assay.** A quantitative assay for HLA-A2.1 binding peptides based on the inhibition of binding of the fluorescent labeled standard peptide Hbc 18-27 F to C6



(FLPSDCFPSV) to recombinant HLA-A2.1 protein and b2-microglobulin was used <sup>26,27</sup>. In short, HLA-A2.1 concentrations yielding approximately 40-60% bound fluorescent standard peptide were used with 15 pmol/well (150 nM) b2-microglobulin (Sigma). Various doses of the test peptides were coincubated with 100 fmol/well (1 nM) fluorescent standard peptide, HLA-A2.1 and b2-microglobulin for 1 day at room temperature in the dark in a volume of 100 ml in assay buffer. The percent of MHC-bound fluorescence was determined by gel filtration and the 50% inhibitory dose was deduced for each peptide using one-site competition non-linear regression analysis with the prismgraph software. Synthetic peptides were manufactured on a Abimed 422 multiple peptide synthesizer (Abimed, Langenfeld, Germany) and were more than 90% pure as checked by reverse phase HPLC.

**RT-PCR amplification and sequencing of KIAA0223 region coding for HA-1.**

Total or mRNA was prepared from BLCL using the RNAzol methode (Cinaa/Biotech Laboratories, Houston, TX) or according to manufacturer's instructions (QuickPrep mRNA purification Kit, Pharmacia Biotech). CDNA was synthesized with 1 mg RNA as template and with KIAA0223 based reverse primer 5'-GCTCCTGCATGACGCTCTGTCTGCA-3'. To amplify the HA-1 region of KIAA0223 the following primers were used: Forward primer 5'-GACGTCGTCGAGGACATCTCCCAT-3' and reverse primer 5'-GAAGGCCACAGCAATCGTCTCCAGG-3'. Cycle parameters used were denaturation 95 °C, 1 min, annealing 58 °C, 1 min and extension 72 °C, 1 min (25 cycles). The PCR-products were purified using the Magic PCR-Preps DNA purification System (Promega) and direct cloned using the pMosBlue T-vector kit (Amersham LIFE SCIENCE). Six independent colonies from each individual were sequenced using the T7-sequencing kit (Pharmacia Biotech).

**HA-1 allele specific PCR amplification.**

In the case of HA-1 allele specific PCR amplification, cDNA was synthesized as described above. A PCR amplification was

performed with allele specific forward primers: for the HA-1<sup>H</sup> allele primer H1: 5'-CCT-TGA-GAA-ACT-TAA-GGA-GTG-TGT-GCT-GCA-3', for the HA-1<sup>R</sup> allele primer R1: 5'-CCT-TGA-GAA-ACT-TAA-GGA-GTG-TGT-GTT-GCG-3' and for both reaction the reverse primer as described above was used. Cycle parameters used were denaturation 95 °C, 1 min, annealing 67 °C, 1 min and extension 72 °C, 1 min (25 cycles).

**Cloning and expression of HA-1<sup>H</sup> and HA-1<sup>R</sup> allelic region of**

**KIAA0223.** A forward KIAA00223 based PCR primer containing an

- 10 ATG startcodon (5'-CCG-GCA-TGG-ACG-TCG-TCG-AGG-ACA-TCT-CCC-ATC-3') and a reverse KIAA0223 based PCR primer containing a translational stop signal (5'-CTA-CTT-CAG-GCC-ACA-GCA-ATC-GTC-TCC-AGG-3') were designed and used in a RT-PCR reaction with cDNA derived from an homozygous HA-1<sup>H</sup> and a homozygous  
15 HA-1<sup>R</sup> BLCL. Cycle parameters used were denaturation 95 °C, 1 min, annealing 60 °C, 1 min and extension 72 °C, 1 min (25 cycles). The desired PCR-products were purified using the Magic PCR-Preps DNA purification System (Promega). The purified DNA was direct cloned using the pMosBlue T-vector  
20 kit (Amersham LIFE SCIENCE) and recloned in the eukaryotic pCDNA3.1(+) vector under the control of a CMV promotor. Transient cotransfections were performed with HLA-A2.1 in Hela cells using DEAE-Dextran coprecipitation. After 3 days of culture HA-1 specific T cells were added and after 24  
25 hours the TNFa release was measured in the supernatant using WEHI cells <sup>28</sup>.

- Peptides:** HA-1 and HA-2 peptides were synthesized using a  
30 semi automatic multiple peptide synthesizer <sup>4, 39</sup>. The purity of the peptides was checked by reversed phase high pressure liquid chromatography (HPLC)

**Antigen Presenting Cells:**

- PBMC** were isolated by ficoll-hypaque density gradient  
35 separation of blood collected with manual hemapheresis.

**Monocytes** were isolated by plastic adherence during PBDC enrichment.

**PBDC** were enriched from PBMC by depletion of T cells, monocytes, B and NK cells as described earlier. Briefly, T cells were depleted by sheep red blood erythrocyte rosetting. Non-T cells were cultured 36 h at 37°C in RPMI + 10 % autologous plasma. After depleting monocytes non adherent cells were layered on 14.5% metrizamide gradients and centrifugated. The light density PBDC were recovered from the interphase. PBDC were identified by FACS being negative for CD3, CD14, CD16 and CD19 and positive for HLA-DR. The preparations contained 2-6 x 10<sup>6</sup> cells with a DC content of 20-50%. In some cases the light density cells were further depleted from CD14 and CD19 cells using antibody coated magnetic beads.

**BMDC** were differentiated from bone marrow CD34+ cells (isolated using CD34+ isolation kit, MACS, Bergisch Gladbach, Germany) by culturing with 100 ng/ml FLT3-ligand (Genzyme, Leuven; Belgium), 30 ng/ml IL-3, 25 ng/ml SCF (Genzyme) 50 U/ml TNF- $\alpha$  (Genzyme), 250 U/ml GM-CSF (Genzyme) for 10 to 14 days. The cultures contained 20-60% DC as detected by high levels of DR and negative expression of CD3/CD14/CD16/CD19.

**Ex vivo induction of HA-1 and HA-2 specific CTLs:** APC were pulsed with HA-1 or HA-2 peptides (both 10 mg/ml) for 90 min. at 37°C in serum free AIM-V medium. After washing, APC and 10-15 x 10<sup>6</sup> responder cells (CD4 depleted autologous PBMC) were cultured at different APC: responder cell ratios depending on the type of APC (5:1, 1:3 and 1:10 for PBMC, Mo and DC, respectively) in 24 well culture plates. Culture medium was RPMI supplemented with 10 % autologous plasma, 1U/ml IL-2 (Cetus), 1 U/ml IL-12 (Genzyme). The cells were kept at 37°C in an humidified, 5% CO<sub>2</sub> air mixture. At day 5, 10 U/ml of IL-2 was added. Starting from day seven, the T cell cultures were restimulated weekly with peptide pulsed autologous monocytes. 10 U/ml of IL-2 was added 24 h. after

each restimulation. The T cell lines were expanded with 10-20 U/ml IL-2 containing culture medium.

**Cytotoxicity ( $^{51}\text{Cr}$  release) assays:** Standard 4 h  $^{51}\text{Cr}$  release assays using PHA-blasts, EBV-BLCL and fibroblasts and

- 5 leukemic cells as target cells were performed as described before<sup>8</sup>. The percent specific lysis was calculated using the following formula:  $100 \times (\text{cpm experimental release} - \text{cpm spontaneous release}) / (\text{cpm maximal release} - \text{cpm spontaneous release})$ .

- 10 **Target cells:** EBV-BLCL were generated as described before<sup>8</sup> and cultured in RPMI plus 10 % FCS. PHA activated T cell blasts (PHA-blasts) were obtained by stimulation of PBMC with 0.1 mg/ml PHA (Wellcome) during 72h. PHA-blasts were expanded with medium containing 20 U/ml IL-2. Skin
- 15 fibroblasts of an HLA-A2+, HA-1+, HA-2+ healthy individual were isolated, cultured and tested as described before<sup>8</sup>. In short, fibroblasts were trypsinized and cultured in the wells of 96 well flat bottomed microtiter culture plates at a concentration of  $3 \times 10^3$  cells/well with or without addition of
- 20 IFN-g and TNF-a (both 300U/ml) during 72 h. When indicated, target cells were pulsed with HA-1 or HA-2 peptides (both 10 mg/ml) during  $^{51}\text{Cr}$  labeling.

- Leukemia patients' (AML or ALL) PBMC or BM containing >95% morphologically recognizable malignant cells were assigned as
- 25 leukemic cells. Leukemic cells were thawed and cultured in RPMI plus 10% human serum for 72 h with or without addition of IFN-g and TNF-a (both 300 u/ml) before using as target cells.

- In vivo induced mHag specific T cell clones:** In vivo induced,
- 30 mHag HA-1 and HA-2 specific CD8+ CTL clones were isolated from post BMT leukemia patients, and were documented in detail<sup>35</sup>.

**Brief description of the drawings**

**Table 1.** KIAA0223 sequence polymorphism in mH HA-1 positive and HA-1 negative individuals.

- 5 Sequencing of HA-1 region in KIAA0223 gene in HA-1 +/+ and HA-1-/- homozygous individuals and KG-1 revealed two alleles differing in two nucleotides resulting in a one amino acid difference (H to R) and designated HA-1<sup>H</sup> and HA-1<sup>R</sup>. For DH and vR 6 independent PCR products were sequenced. For KG-1 8  
10 PCR products were sequenced.

- Figure 1.** Reconstitution of HA-1 with HPLC fractionated peptides eluted from HLA-A2.1 molecules in a <sup>51</sup>Cr-release assay with mH HA-1 specific T cell clone 3HA15. a. Peptides  
15 were eluted from 90.10<sup>9</sup> HA-1 and HLA-A2.1 positive Rp cells and separated using reverse phase HPLC with HFBA as organic modifier. b. Fraction 24 of the first HPLC dimension that contained HA-1 activity was further fractionated by reverse phase HPLC with TFA as organic modifier. c. HA-1 containing  
20 fraction 27 of the second gradient was further chromatographed with a third shallower gradient consisting of 0.1% acetonitrile/min. Background lysis of T2 by the CTL in the absence of any peptides was in a 3%, in b and c 0%. Positive control lysis was in a 99%, in b 74% and in c 66%.  
25 d. Determination of candidate HA-1 peptides. HPLC fraction 33 from the separation in Fig. 1c. was chromatographed with an on-line microcapillary column effluent splitter and analysed by electrospray ionization mass spectrometry and a <sup>51</sup>Cr-release assay. HA-1 reconstituting activity as percent  
30 specific release was compared with the abundance of peptide candidates measured as ion current.

- Figure 2.** Sequencing of mH HA-1 peptide by tandem mass spectrometry. a. Collision activation dissociation mass  
35 spectrum of peptide candidate with m/z of 513. b. Reconstitution assay with different concentrations of

synthetic mH HA-1 peptide with three HA-1 specific T cell clones, 3HA15, clone 15 and 5W38. Background lysis of T2 by the CTL in the absence of any peptide was for 3HA15 4%, for clone 15 10% and for 5W38 2%. Positive control lysis was for  
5 3HA15 46%, for clone 15 47% and 5W38 48%.

**Figure 3.** KIAA0223 polymorphism exactly correlated with mH antigen HA-1 phenotype. a. The HA-1 region of KIAA0223 was sequenced in a HA-1 mH antigen typed family. 6 PCR products  
10 of each family member were sequenced. Family members 00, 07 and 09 expressed the HA-1<sup>R</sup> in all 6 PCR products. Family member 01 expressed the HA-1<sup>H</sup> allele in 2 PCR products and the HA-1<sup>R</sup> allele in 4 PCR products. Family member 02 expressed the HA-1<sup>H</sup> allele in 3 PCR products and the HA-1<sup>R</sup>  
15 allele in 3 PCR products. Family member 08 expressed the HA-1<sup>H</sup> allele in 4 PCR products and the HA-1<sup>R</sup> allele in 2 PCR products b. HA-1 allele specific PCR reaction in a HA-1 mH antigen typed family correlated exactly with the HA-1 phenotype. The sizes of the resulting PCR products were  
20 consistent with the expected sizes deduced from the cDNA sequence. c. Transfection of the HA-1<sup>H</sup> allele of KIAA0223 leads to recognition by mH HA-1 specific T cells. The HA-1<sup>H</sup> and the HA-1<sup>R</sup> coding sequence of KIAA0223 were together with HLA-A2.1 transfected into Hela cells. After 3 days the HA-1  
25 specific CTL clones 5W38 and 3HA15 were added and after the 24 hours TNFa release was measured in the supernatant. The clone Q66.9 is specific for the influenza matrix peptide 58-66. No TNFa production was observed after transfection of the pcDNA3.1(+) vector alone (results not shown).

30

**Figure 4.** a. Binding of HA-1<sup>H</sup> and HA-1<sup>R</sup> peptides to HLA-A2.1. The binding of HA-1<sup>H</sup> and HA-1<sup>R</sup> peptides were assayed for their ability to inhibit the binding of fluorescent peptide FLPSDCFPSV to recombinant HLA-A2.1 and b2-microglobulin in a  
35 cell free peptide binding assay. One representative experiment is shown. The IC50 is determined on the results of

4 experiments and was 30 nM for VLHDDLLEA and 365 nM for VLRDDLLEA. b. Reconstitution assay with different concentrations of synthetic HA-1<sup>R</sup> peptide with HA-1 specific T cells. The HA-1<sup>R</sup> peptide was titrated and preincubated with T2 cells. Three HA-1 specific T cell clones, 5W38, 3HA15 and clone 15 were added and a 4 hr <sup>51</sup>Cr-release assay was performed. Background lysis of T2 by the CTL in the absence of any peptide was for 3HA15 4%, for clone 15 10% and for 5W38 2%. Positive control lysis was for 3HA15 46%, for clone 15 47% and 5W38 48%.

**Figure 5.** Cytotoxic T cell activity against peptide pulsed and mHag positive target cells by two ex vivo induced HA-1 (a, b) and two ex vivo induced HA-2 specific CTLs (c, d). CTLs shown in a,c,d are induced using PBDC, whereas CTLs shown in b are induced using BMDC. Target cells: autologous PHA blasts (◇); autologous PHA blasts pulsed with peptide (◆); EBV-LCL positive for HA-1 (n=4) or HA-2 (n=3) (Δ); EBV-LCL negative for HA-1 (n=3) or HA-2 (n=3) (○); HA-1 or HA-2 negative EBV-LCL pulsed with HA-1 or HA-2 peptide (\*).

**Figure 6.** Hematopoietic cell restricted cytolysis mediated by in vivo (a,c) and ex vivo (b,d) induced HA-1(a,b) and HA-2 (c,d) specific CTLs. All target cells were derived from the same HLA-A2+, HA-1+, HA-2+ blood donor. Target cells: PHA blasts (Δ); fibroblasts (◆); Fibroblasts cultured with IFN-γ+ TNF-α (both 300 U/ml) (\*); Fibroblasts cultured with IFN-γ plus TNF-α and pulsed with 10 μg/ml peptide (○).

**Figure 7.** Lysis of HA-1<sup>+</sup> (a,b,c) or HA-2<sup>+</sup> (d,e,f) positive leukemic cells by in vivo (b,e) and ex vivo (c,f) induced HA-1 and HA-2 specific CTLs. Lysis of target cells by control HLA-A2 specific CTL clone is shown in a and d. Target cells: HA-1 or HA-2 negative EBV-LCL (—), HA-1 or HA-2 positive EBV-LCL (Δ), Leukemic cells positive for HA-1 (n=4) or HA-2





REFERENCES

1. Beatty, P.G. et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. *Transplantation* 51, 443-447 (1997).
2. Marks, D.I. et al. Allogeneic bone marrow  
5 transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years. *Ann. Intern. Med.* 119, 207-214 (1993).
3. Goulmy, E. et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the  
10 development of graft-versus-host disease after bone marrow transplantation. *N. Engl. J. Med.* 334, 281-285 (1996).
4. den Haan, J.M. et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. *Science* 268, 1476-1480 (1995).
- 15 5. Wang, W. et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein [see comments]. *Science* 269, 1588-1590 (1995).
6. Meadows, L. et al. The HLA-A\*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that  
20 significantly affects T cell recognition. *Immunity*. 6, 273-281 (1997).
7. van Els, C.A. et al. Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. *Immunogenetics* 35, 161-165 (1992).
- 25 8. de Bueger, M., Bakker, A., van Rood, J.J., Van der Woude, F. & Goulmy, E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. *J. Immunol.*  
30 149, 1788-1794 (1992).
9. Van Lochem, E., van der Keur, M., Mommaas, A.M., de Gast, G.C. & Goulmy, E. Functional expression of minor histocompatibility antigens on human peripheral blood

- dendritic cells and epidermal Langerhans cells. *Transpl. Immunol.* 4, 151-157 (1996).
10. van der Harst, D. et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. *Blood* 83, 1060-1066 (1994).
11. Schreuder, G.M. et al. A genetic analysis of human minor histocompatibility antigens demonstrates Mendelian segregation independent of HLA. *Immunogenetics* 38, 98-105 (1993).
12. Goulmy, E., Pool, J. & van den Elsen, P.J. Interindividual conservation of T-cell receptor beta chain variable regions by minor histocompatibility antigen-specific HLA-A\*0201-restricted cytotoxic T-cell clones. *Blood* 85, 2478-2481 (1995).
13. Ruppert, J., Sidney, J., Celis, E., Kubo, R.T., Grey, H.M. & Sette, A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. *Cell* 74, 929-937 (1993).
14. Chen, Y. et al. Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. *J. Immunol.* 152, 2874-2881 (1994).
15. Loveland, B., Wang, C.R., Yonekawa, H., Hermel, E. & Lindahl, K.F. Maternally transmitted histocompatibility antigen of mice: a hydrophobic peptide of a mitochondrially encoded protein. *Cell* 60, 971-980 (1990).
16. Loveland, B.E., Fischer Lindahl, K. The definition and expression of minor histocompatibility antigens. McCluskey J, editors. *Antigen processing and recognition*. London: CRC Press, 9, 173-92 (1991).
17. Lindahl, K.F. Minor histocompatibility antigens. *Trends. Genet.* 7, 219-224 (1991).
18. Perreault, C., Jutras, J., Roy, D.C., Filep, J.G. & Brochu, S. Identification of an immunodominant mouse minor

- histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versus-host disease. *J. Clin. Invest.* 98, 622-628 (1996).
19. Morse, M.C. et al. The COI mitochondrial gene encodes a minor histocompatibility antigen presented by H2-M3. *J. Immunol.* 156, 3301-3307 (1996).
20. Scott, D.M. et al. Identification of a mouse male-specific transplantation antigen, H-Y. *Nature* 376, 695-698 (1995).
- 10 21. Greenfield, A. et al. An H-YDb epitope is encoded by a novel mouse Y chromosome gene. *Nat. Genet.* 14, 474-478 (1996).
22. Martin, P.J. Increased disparity for minor histocompatibility antigens as a potential cause of increased GVHD risk in marrow transplantation from unrelated donors compared with related donors.. *Bone Marrow Transplant.* 8, 217-223 (1991).
- 15 23. Goulmy, E., Gratama, J.W., Blokland, E., Zwaan, F.E. & van Rood, J.J. A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease. *Nature* 302, 159-161 (1983).
- 20 24. de Bueger, M. et al. Isolation of an HLA-A2.1 extracted human minor histocompatibility peptide. *Eur. J. Immunol.* 23, 614-618 (1993).
- 25 25. Hunt, D.F. et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. *Science* 255, 1261-1263 (1992).
26. Ottenhoff, T.H.M., Geluk, A., Toebes, M., Benckhuijsen, W.E., van Meijgaarden, K.E. & Drijfhout, J.W. A sensitive fluorometric assay for quantitatively measuring specific peptide binding to HLA class I and class II molecules. *J. Immunol. Methods* 200, 89-97 (1997).
- 30 27. Tan, T.L.R., Geluk, A., Toebes, M., Ottenhoff, T.H.M. & Drijfhout, J.W. A novel, highly efficient peptide-HLA class I

binding assay using unfolded heavy chain molecules;  
identification of HIV-1 derived peptides that bind to  
HLA-A\*0201 and HLA-A\*0301. *Submitted* (1997).

28. Traversari, C. et al. Transfection and expression of a  
5 gene coding for a human melanoma antigen recognized by  
autologous cytolytic T lymphocytes. *Immunogenetics* 35,  
145-152 (1992).
29. O'Reilly, R.J. Allogeneic bone marrow transplantation:  
Current status and future directions. *Blood* 62: 941-964  
10 (1983)
30. Horowitz, M.M. et.al. Graft-versus-leukemia reactions  
after bone marrow transplantation. *Blood* 75: 555-562. (1990)
31. Ringden, O. et.al. Allogeneic bone marrow transplantation  
for leukemia: factors of importance for long-term survival  
15 and relapse. *Bone Marrow Transplant* 3: 281-290. (1988)
32. Kolb, H.J. and Holler, E. Adoptive immunotherapy with  
donor lymphocyte transfusions. *Curr Opin Oncol* 9:  
139-145. (1997)
33. Kolb, H.J. et.al. Graft-versus-leukemia effect of donor  
20 lymphocyte transfusions in marrow grafted patients. European  
Group for Blood and Marrow Transplantation Working Party  
Chronic Leukemia. *Blood* 86: 2041-2050. (1995)
34. Gratwohl, A. et.al. Acute graft-versus-host disease:  
grade and outcome in patients with chronic myelogenous  
25 leukemia. Working Party Chronic Leukemia of the European  
Group for Blood and Marrow Transplantation. *Blood* 86:  
813-818. (1995)
35. Goulmy, E. Human minor histocompatibility antigens: new  
concepts for marrow transplantation and adoptive  
30 immunotherapy. *Immunol Rev* 157: 125-140. (1997)
36. Niederwieser, D. et.al. Correlation of minor  
histocompatibility antigen-specific cytotoxic T lymphocytes  
with graft-versus-host disease status and analyses of tissue  
distribution of their target antigens. *Blood* 81:  
35 2200-2208. (1993)

37. Faber, L.M. et.al. Recognition of clonogenic leukemic cells, remission bone marrow and HLA- identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. *J Clin Invest* **96**: 877-883. (1995)
38. Falkenburg, J.H.F. et.al. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. *J Exp Med* **174**: 27-33. (1991)
39. den Haan, J.M. et.al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. *Science* **279**: 1054-1057. (1998)
40. Banchereau, J. and Steinman, R.M. Dendritic cells and the control of immunity. *Nature* **392**: 245-252. (1998)
41. Bonini, C. et.al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [see comments]. *Science* **276**: 1719-1724. (1997)
42. Heslop, H.E. et.al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. *Nature Medicine* **2**: 551-555. (1996)
43. van Lochem, E.G., Schreuder, G.M., Tilanus, M.G., de Gast, G.C., and Goulmy, E. Dendritic cells induce HLA-DP-specific T-cell proliferation between MLR- negative siblings. *Immunogenetics* **41**: 134-138. (1995)

Cell	CTL analysis HA-1 phenotype	KIAA0223 sequence	Nr. of clones sequenced	DNA analysis HA-1 phenotype
DH	HA-1 <sup>-/-</sup>	GAGTGTGTGTTGCGTGACGACCTCCTTGAGGCCCGCCG E C V L R D D L L E A R R	(6/6 clones)	HA-1 <sup>R</sup> /HA-1 <sup>R</sup>
vR	HA-1 <sup>+/+</sup>	GAGTGTGTGCTGCATGACGACCTCCTTGAGGCCCGCCG E C V L H D D L L E A R R	(6/6 clones)	HA-1 <sup>H</sup> /HA-1 <sup>H</sup>
KG-1	HA-1 <sup>+</sup>	GAGTGTGTGTTGCGTGACGACCTCCTTGAGGCCCGCCG E C V L R D D L L E A R R GAGTGTGTGCTGCATGACGACCTCCTTGAGGCCCGCCG E C V L H D D L L E A R R	(1/8 clones) (7/8 clones)	HA-1 <sup>R</sup> /HA-1 <sup>H</sup>

Table 1

CLAIMS

1. A peptide constituting a T-cell epitope obtainable from the minor Histocompatibility antigen HA-1 comprising the sequence VLXDDLLEA or a derivative thereof having similar functional or immunological properties, wherein X represents  
5 a histidine or an arginine residue.
2. An immunogenic polypeptide obtainable from the minor Histocompatibility antigen HA-1 comprising the sequence VLXDDLLEA or a derivative thereof having similar functional or immunological properties, wherein X represents a histidine  
10 or an arginine residue.
3. A peptide or polypeptide according to claim 1 or 2, comprising the sequence VLHDDLLEA.
4. Vaccine comprising an epitope or a polypeptide according to any one of claims 1-3.
- 15 5. A pharmaceutical formulation comprising an epitope or a polypeptide according to any one of claims 1-3.
6. Peptide or polypeptide according to claims 1-3 for use as a medicine.
7. Use of a peptide or polypeptide according to claims 1-3  
20 in the preparation of a medicament for the induction of tolerance for transplants to prevent rejection and/or Graft versus Host disease or to treat (auto)immune disease.
8. A method for the elimination of a group of (neoplastic) hematopoietic cells presenting a peptide in the context of  
25 HLA class 1 according to any one of claims 1-3, whereby elimination is induced directly or indirectly by specific recognition of said peptide in said context.
9. Analog of the peptide according to claim 1, which is an antagonist for the activity of T cells recognizing said  
30 peptide.
10. Method for the generation of antibodies, T cell receptors, anti-idiotypic B-cells or T-cells, comprising the step of immunization of a mammal with a peptide or a polypeptide according to claim 1 or 2.

11. Antibodies, T-cell receptors, B-cells or T-cells obtainable by the method of claim 10.

12. A method for the generation of a cytotoxic T-cell against a minor antigen, comprising contacting a hematopoietic cell, preferably a dendritic cell with a peptide, preferably in the context of HLA class I, or a polypeptide according to anyone of claims 1-3.

13. A method according to claim 12, wherein said hematopoietic cell is negative for said minor antigen.

14. A method according to claim 12 or 13, wherein said minor antigen is HA-1.

15. A method according to any one of claims 12-14 wherein said contacting is carried out ex vivo.

16. A method according to any one of claims 12-15, wherein said cytotoxic T-cell is provided with a suicide gene.

17. A method according to anyone of claims 12-16, whereby said cytotoxic T-cell is immortalized.

18. A cytotoxic T-cell or a derivative or an active fragment thereof, obtainable by a method according to any one of claims 12-17.

19. A cytotoxic T-cell according to claim 18, which is capable of expansion.



**Abstract**

A peptide sequence of the so-called minor H antigen. The minor H antigens are associated with Graft versus Host disease. The peptide and its derivatives find many uses in bone marrow transplantation, organ transplantation, and in the treatment of leukemia. The peptide and its derivatives can be incorporated into vaccines and pharmaceutical formulations, and they can be used in diagnostic test kits. The peptide is derived from the HA-1 minor antigen, and has the sequence VLXDDLLEA, wherein X represents a histidine or arginine residue. Both donors and recipients in bone marrow transplantation can be treated with the peptides, optionally in combination with other peptides, coupled to carriers, and with suitable excipients and/or adjuvants.

WO 99/05173

1/12

PCT/NL98/00424




Figure 1

WO 99/05173

2/12

PCT/NL98/00424




Figure 1D

WO 99/05173

3/12

PCT/NL98/00424




Figure 2A

WO 99/05173

4/12

PCT/NL98/00424




Figure 2B

WO 99/05173

PCT/NL98/00424

5/12




Figure 3A

WO 99/05173

PCT/NL98/00424





Figure 3B

WO 99/05173

PCT/NL98/00424

7/12

Figure 3C




09480760-043400



WO 99/05173

8/12

PCT/NL98/00424



09484750-012100

WO 99/05173

PCT/NL98/00424

9/12




Figure 4B


09489760-012100

WO 99/05173

10/12

PCT/NL98/00424

## HA-1 specific CTL



## HA-2 specific CTL




Figure 5

WO 99/05173

11/12

PCT/NL98/00424




Figure 6

WO 99/05173

12/12

PCT/NL98/00424





Figure 7

09489760-012100

# SEQUENCE LISTING

<110> Rijksuniversiteit Te Leidin  
 Goulmy, Elsa A.J.M  
 Hunt, Donald F  
 Hard, Victor H

<120> The HA-1 Antigen

<130> 2183-4285US

<140> to be assigned

<141> 2000-01-21

<150> PCT/NL98/00424

<151> 1998-07-23

<160> 16

<170> PatentIn Ver. 2.1

<210> 1

<211> 9

<212> PRT

<213> Histocompatibility antigen

<220>

<221> PEPTIDE

<222> (3)

<223> AMINO ACID X REPRESENTS A HISTIDINE OR AN ARGININE  
 RESIDUE

<400> 1

Val Leu Xaa Asp Asp Leu Leu Glu Ala

1

5

<210> 2

<211> 9

<212> PRT

<213> Histocompatibility antigen

<400> 2

Val Leu His Asp Asp Leu Leu Glu Ala

1

5

<210> 3

<211> 9  
<212> PRT  
<213> Histocompatibility antigen

<220>  
<221> PEPTIDE  
<222> (2)  
<223> AMINO ACID X REPRESENTS EITHER ISOLEUCINE OR  
LEUCINE RESIDUES

<400> 3  
Tyr Xaa Thr Asp Arg Val Met Thr Val  
1 5

<210> 4  
<211> 9  
<212> PRT  
<213> Histocompatibility antigen

<220>  
<221> PEPTIDE  
<222> (2)..(7)  
<223> AMINO ACIDS X REPRESENT LEUCINE OR ISOLEUCINE  
RESIDUES

<400> 4  
Val Xaa His Asp Asp Xaa Xaa Glu Ala  
1 5

<210> 5  
<211> 9  
<212> PRT  
<213> KIAA0223 partial complementary DNA

<400> 5  
Val Leu Arg Asp Asp Leu Leu Glu Ala  
1 5

<210> 6  
<211> 25  
<212> DNA  
<213> Unknown Organism

<220>  
<223> Description of Unknown Organism:Reverse primer

<400> 6  
gctcctgcat gacgctctgt ctgca 25

<210> 7  
<211> 24  
<212> DNA  
<213> Unknown Organism

<220>  
<223> Description of Unknown Organism:Forward primer

<400> 7  
gacgtcgtcg aggacatctc ccat 24

<210> 8  
<211> 25  
<212> DNA  
<213> Unknown Organism

<220>  
<223> Description of Unknown Organism:Reverse Primer

<400> 8  
gaaggccaca gcaatcgtct ccagg 25

<210> 9  
<211> 30  
<212> DNA  
<213> Unknown Organism

<220>  
<223> Description of Unknown Organism:HA-1" allele  
primer H1

<400> 9  
ccttgagaaa cttaaggagt gtgtgctgca 30

<210> 10  
<211> 30  
<212> DNA  
<213> Unknown Organism

<220>



<223> Description of Unknown Organism:HA-1r allele  
primer R1

<400> 10

ccttgagaaa cttaaggagt gtgtgttgcg

30

<210> 11

<211> 33

<212> DNA

<213> Forward KIAA00223 based PCR primer

<400> 11

ccggcatgga cgtcgtcgag gacatctccc atc

33

<210> 12

<211> 30

<212> DNA

<213> Reverse KIAA00223 based PCR primer

<400> 12

ctacttcagg ccacagcaat cgtctccagg

30

<210> 13

<211> 38

<212> DNA

<213> Unknown Organism

<220>

<223> Description of Unknown Organism:HA-1-/-

<400> 13

gagtgtgtgt tgcgtagaca cctccttgag gcccgccg

38

<210> 14

<211> 13

<212> PRT

<213> Unknown Organism

<220>

<223> Description of Unknown Organism:HA-1-/-

<400> 14

Glu Cys Val Leu Arg Asp Asp Leu Leu Glu Ala Arg Arg

1

5

10

<210> 15  
<211> 38  
<212> DNA  
<213> Unknown Organism

<220>  
<223> Description of Unknown Organism:HA-1+/+

<400> 15  
gagtgtgtgc tgcattgacga cctccttgag gcccgccg 38

<210> 16  
<211> 13  
<212> PRT  
<213> Unknown Organism

<220>  
<223> Description of Unknown Organism:HA-1+/+

<400> 16  
Glu Cys Val Leu His Asp Asp Leu Leu Glu Ala Arg Arg  
1 5 10